Regeneron price target raised to $915 from $815 at Barclays

Barclays analyst Carter Gould raised the firm’s price target on Regeneron Pharmaceuticals to $915 from $815 and keeps an Overweight rating on the shares. The analyst added chronic obstructive pulmonary disease to the model following yesterday’s data, modeling 2030 sales in COPD of $4B and global sales across indications to $25B. Coupled with "underappreciated" operating margin expansion from the mid-to-high 50%s today, the firm sees Dupixent sales driving Sanofi collaboration revenues from $2.9B in 2022 to $10.7B in 2030. Barclays says Regeneron shares "can continue to work over the next 12 months."